NCT05122026View on ClinicalTrials.gov

Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

252

Participants

Timeline

Start Date

January 17, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

March 31, 2025

Conditions
HIV SeropositivityPregnancyTuberculosis Infection
Interventions
DRUG

Rifapentine

As included in arm/group description

DRUG

Isoniazid

As included in arm/group description

Trial Locations (3)

1632

RECRUITING

The Aurum Institute: Tembisa Clinical Research Centre, Tembisa

2571

RECRUITING

Peri Natal HIV Research Unit - Klerksdorp Tshepong Hospital, Klerksdorp

7505

RECRUITING

FAMily Centre for Research with Ubuntu (FAMCRU), Cape Town

All Listed Sponsors
collaborator

Johns Hopkins University

OTHER

collaborator

Weill Medical College of Cornell University

OTHER

collaborator

University of Washington

OTHER

lead

The Aurum Institute NPC

OTHER